Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 6/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | HTR1D | P28221 | 2/20 | 0.47 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17912801 | 0.86 | HTR1B (0.37) | HTR1BSLC6A4SLC6A2HTR1D | |
| SCHEMBL28386012 | 0.83 | HTR1B (0.48) | HTR1BSLC6A4SLC6A2HTR1DNR2E1 | |
| SCHEMBL6913436 | 0.80 | HTR1B (0.46) | HTR1BSLC6A4SLC6A2HTR1DNR2E1 | |
| SCHEMBL23544497 | 0.80 | SLC6A4 (0.46) | HTR1BSLC6A4SLC6A2NR2E1HRH1 | |
| SCHEMBL20506758 | 0.78 | KDM4E (0.54) | HTR1BSLC6A4SLC6A2HTR1DNR2E1 | |
| SCHEMBL5715049 | 0.78 | SLC6A4 (0.50) | HTR1BSLC6A4SLC6A2HTR1D | |
| SCHEMBL27478671 | 0.78 | PPARG (0.51) | HTR1BSLC6A4SLC6A2 | |
| SCHEMBL27920845 | 0.77 | MCHR1 (0.56) | HTR1BSLC6A4SLC6A2HTR1DNR2E1 | |
| SCHEMBL28054515 | 0.76 | SLC6A4 (0.46) | HTR1BSLC6A4SLC6A2HTR1D | |
| SCHEMBL6915137 | 0.76 | HTR1B (0.45) | HTR1BSLC6A4SLC6A2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | HTR1B 914/4885SLC6A4 2865/4885SLC6A2 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.